Is TB-500 Banned? WADA and FDA Status
TB-500 is prohibited in sport at all times and approved as a medicine nowhere. It is also not thymosin beta-4 — analysis found a short synthetic fragment.
Most of what is written about TB-500 describes thymosin β4. The two names are used as though they were interchangeable. They are not, and the difference is the single most useful thing to understand about this compound.
What is thymosin β4, exactly?
Thymosin β4 (Tβ4) is a 43-amino-acid protein found in nearly every human cell type. Its main known job is binding actin — it sequesters actin monomers and helps regulate how the cytoskeleton assembles and disassembles. That role puts it near processes that matter in wound repair, cell migration and inflammation, which is why it attracted therapeutic interest in the first place.
It has been studied as a candidate treatment in several settings, including registered clinical trials. A randomised, placebo-controlled Phase II study of a thymosin β4 ophthalmic solution for dry eye is one example: real human research, conducted on a specific formulation, for a specific indication, with a specific route of administration.
What TB-500 turned out to be
When analytical chemists examined material sold under the name TB-500, they did not find the 43-amino-acid protein. Two 2012 papers characterised the contents:
| Paper | What it found |
|---|---|
| Drug Testing and Analysis | An N-terminal acetylated peptide corresponding to residues 17–23 of Tβ4 — seven amino acids, not forty-three |
| Journal of Chromatography A | Described TB-500 as a synthetic version of an active region of Tβ4 and developed detection methods for urine and plasma |
That fragment includes the actin-binding motif, which is the rationale for making it. But a seven-residue peptide and a 43-residue protein are different molecules with different stability, different distribution and different behaviour in the body.
This is the core problem with the literature as it is usually presented. Search for TB-500 and you will find summaries of Tβ4 research — the wound-healing work, the cardiac work, the corneal work. Almost none of it was performed on the fragment.
What the evidence supports, and where it stops
Splitting the two apart makes the picture clearer:
- Thymosin β4 has a substantial preclinical literature and some human trial activity in defined indications. It is not an approved medicine for musculoskeletal injury.
- TB-500, the fragment, has essentially no human efficacy evidence. What exists is analytical chemistry — how to identify it, how to detect it in a doping sample.
A 2026 review in Sports Medicine examined approved and unapproved peptide therapies marketed for musculoskeletal injuries and athletic performance. The recurring finding across this category is a gap between the confidence of the marketing and the state of the evidence, and TB-500 sits squarely inside it.
None of this makes the compound uninteresting. It makes the claims about it unsupported, which is a different statement — and the honest one.
Is TB-500 banned in sport?
Yes, and neither substance holds a marketing authorisation for human therapeutic use in the United States or the European Union either.
For anyone who competes, the position is unambiguous. WADA’s Prohibited List covers thymosin-β4 and its derivatives — TB-500 is named as an example — under the growth factors category. That means prohibited at all times, in and out of competition. The 2012 chromatography work exists precisely because laboratories needed a method to find it, so detection is not theoretical.
Anything sold outside a regulated supply chain carries a second problem on top of the evidence one: you cannot know what is in the vial. The analytical papers above are, in effect, documentation of exactly that — someone had to run a mass spectrometer to establish what a product marketed under this name contained.
The July 2026 recommendation
On 23 July 2026 the FDA’s Pharmacy Compounding Advisory Committee recommended that TB-500 be added to the 503A bulk drug substances list. It is a recommendation, not a rule — the first of four stages, with no deadline on the three that follow, and the sequence is set out here.
Two things it does not touch. It is not an approval, so the absence of a marketing authorisation described above is unchanged. And it has no effect whatever on the sport position: WADA’s Prohibited List operates independently of FDA compounding policy, and a substance can be compoundable in a US pharmacy and still prohibited at all times in competition.
The practical part
If a compound is being tracked, the handling questions are the same ones that apply to any peptide, and they are not affected by how strong the efficacy evidence is. Lyophilised material is stable in the cold and dark and becomes far less stable once water is added — the mechanics of that are covered in peptide storage and the arithmetic of turning a vial into a measured volume is covered in reconstitution and concentration. If you want to run the numbers directly, the reconstitution calculator does the conversion.
How often is a harder question than it looks, and for this compound it has no answer: TB-500 is one of the entries in the half-life table with no published human figure at all, because the work done on the fragment was analytical rather than pharmacokinetic.
What a record cannot do is resolve the question above it. Tracking a compound carefully tells you what you took and when; it does not tell you whether the evidence supports taking it. On this one, the published record is thin, and the distinction between the fragment and the protein is where most of the confusion starts.
Frequently asked questions
Is TB-500 the same as thymosin beta-4?
No. Thymosin β4 is a 43-amino-acid protein that occurs naturally in human cells. Analytical work on products sold as TB-500 identified a short synthetic fragment — an N-terminal acetylated peptide corresponding to residues 17–23 — rather than the full protein. Research findings for one do not automatically transfer to the other.
Is TB-500 approved as a medicine?
No. Neither TB-500 nor thymosin β4 holds a marketing authorisation for human therapeutic use in the United States or the European Union. Thymosin β4 has been studied in registered clinical trials for specific indications, but studied is not the same as approved.
Is TB-500 banned in sport?
Yes. The WADA Prohibited List covers thymosin-β4 and its derivatives, TB-500 among them, in the growth factors section. It is prohibited at all times, both in and out of competition. Doping-control methods for detecting it in urine and plasma were published in 2012.
Does any human trial support TB-500 for injury healing?
No trial has established that. The human trial evidence concerns thymosin β4 in specific formulations and indications — a Phase II study of an ophthalmic solution for dry eye, for example. The musculoskeletal healing claims made for TB-500 rest on animal and cell work, not on completed human efficacy trials.
Sources
- Drug Testing and Analysis (2012) — Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500
- Journal of Chromatography A (2012) — Doping control analysis of TB-500, a synthetic version of an active region of thymosin β4
- Clinical Ophthalmology (2015) — Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled Phase II clinical trial
- Sports Medicine (2026) — Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
- World Anti-Doping Agency — The Prohibited List